Blog

The latest thoughts from Medicines Law & Policy partners.

Imagine if health and trade ministers would meet in one room this week

A earlier version of this commentary was published on 28 November 2021 by Barron's. This is a time of missed opportunities. This week, trade ministers...

How patents, data exclusivity and SPCs interact to extend market exclusivity of medicines: the...

Patents usually confer 20-year exclusive rights on inventions. Data exclusivity laws confer, depending on the country, 5 to 10 years’ exclusive rights over safety...

We need a Global Vaccines Taskforce, not just a British or European one

The European Commission has been heavily criticised for its performance over Covid-19 vaccine supply to European Union Member States. Despite the urgency of the...

ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...

These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...

Current drafts of the WHO Pandemic Accord lack a provision for access to knowhow/trade...

Negotiations are currently taking place at the World Health Organization (WHO) to conclude a new pandemic agreement by May 2024. The objective of the...

The European Commission’s compulsory licensing proposals are sensible but do not go far enough

An earlier version of this comment was published in Barron's on 21 July 2023. A Spanish translation of it is also available from El...

Strong call for transparency on medicine prices, cost of R&D at WHO Fair Pricing...

“Medical innovation has little social value if most people cannot access its benefits…. this is a global human rights issue,” said Mariângela Simão, Assistant...

Humiragate: AbbVie’s desperate attempts to keep its monopoly

A new front has opened in the war against Abbvie's efforts to sustain and secure its Humira market monopoly. This time in The Netherlands...

High medicines prices in Europe – do not Brexit the people

The issues of high priced medicines and problems with access to medicines have for many years been themes belonging to the realm of global...

Medicines Law & Policy responds to US Health and Human Services Department request for...

On 12 December 2023 the US Health and Human Services Department (HHS) posted a notice and request for comments on “the implications of access...